News & Updates

In critically ill patients who have been on invasive mechanical ventilation (IMV) for at least 3 days, a subsequent 3-day course of preventive inhaled amikacin reduced the burden of ventilator-associated pneumonia (VAP) during 28 days of follow-up, findings from the AMIKINHAL trial have shown.

Treatment with the combination of xanomeline plus trospium leads to favourable reduction in positive and negative symptoms in patients with schizophrenia, while being well tolerated, according to data from the phase III EMERGENT-2 trial.

The tricyclic antidepressant amitriptyline, when used at low dose in the second-line treatment setting and titrated according to symptom response and side-effects, is safe and provides relief from symptoms of irritable bowel syndrome (IBS), as shown in the phase III ATLANTIS* trial.

A voice-based conversational artificial intelligence application helps type 2 diabetes (T2D) patients navigate basal insulin titration at home and, in turn, achieve rapid glycaemic control, as reported in a study.

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.